The US Food and Drug Administration (FDA) has approved Dermira Inc.’s Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of excessive armpit sweating, or primary axillary hyperhidrosis, in adult and pediatric patients aged ≥9 years. About 10 million people are affected with the condition, which results in sweating beyond what is needed for regulating normal body temperature, and can affect a person’s psychological well-being and overall quality of life. Dermira Inc. is headquartered in Menlo Park, CA.
Administration: Patients should use 1 cloth to apply Qbrexza to both axillae by wiping the cloth across 1 underarm, one time. Using the same cloth, apply the medication to the other underarm, one time. Qbrexza can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes. Patients should be instructed to wash their hands with soap and water immediately after discarding the used cloth.
Adverse reactions: Most common adverse reactions (incidence ≥2%) are dry mouth, mydriasis, oropharyngeal pain, headache, urinary hesitation, vision blurred, nasal dryness, dry throat, dry eye, dry skin, and constipation. Local skin reactions, including erythema, burning/stinging, and pruritus were also common (>5%).
Dermira receives FDA approval for Qbrexza (glycopyrronium) cloth to treat primary axillary hyperhidrosis. [news release]. Menlo Park, CA: Dermira Inc. June 29, 2018. http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2356602. Accessed July 6, 2018.
Must Reads in FDA Actions
FDA Approves Hyrimoz for Plaque Psoriasis, Sandoz news release; 2018 Oct 31
FDA Approves Seysara for Severe Acne Vulgaris, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
FDA Approves Nuzyra for Acute Skin Infections, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8
FDA Approves Libtayo for Metastatic cSCC, Sanofi news release; 2018 Sep 28